A Pan-ALDH1A Inhibitor Induces Necroptosis in Ovarian Cancer Stem-like Cells

Area of Science:

• Oncology
• Biochemistry

Background:

• Ovarian cancer frequently develops chemotherapy resistance.
• High aldehyde dehydrogenase (ALDH) activity, stemness, and CD133 expression are linked to this resistance.
• ALDH1A family members are implicated in chemotherapy resistance and stemness.

Purpose of the Study:

• To investigate aldehyde dehydrogenase 1A (ALDH1A) family members as a therapeutic target for overcoming chemotherapy resistance in ovarian cancer.
• To evaluate the efficacy of ALDH1A family selective inhibitors (ALDH1Ai) against ovarian cancer stem-like cells (CSCs).

Main Methods:

• Identification and application of two ALDH1A family selective inhibitors (ALDH1Ai).
• Assessment of ALDH1Ai effects on CD133+ ovarian cancer stem-like cells (CSCs).
• Analysis of cell death mechanisms, including necroptosis, mitochondrial uncoupling, and oxidative phosphorylation.
• Evaluation of ALDH1Ai synergy with chemotherapy in vivo models.

Main Results:

• ALDH1Ai preferentially eliminate CD133+ ovarian cancer stem-like cells (CSCs).
• ALDH1Ai induce CSC necroptosis via mitochondrial uncoupling and reduced oxidative phosphorylation.
• ALDH1Ai demonstrate significant synergy with chemotherapy, reducing tumor initiation and enhancing eradication in vivo.

Conclusions:

• The ALDH1A family is a critical therapeutic target for overcoming ovarian cancer chemotherapy resistance.
• ALDH1Ai induce CSC death through necroptosis, offering a novel therapeutic strategy.
• Targeting ALDH1A enzymes can improve treatment outcomes for ovarian cancer patients.